NGLY1 and nervous system disorder: Recently, several groups engineered AAV capsids to cross the BBB more efficiently than AAV9 in mice (45–47) or nonhuman primates (NHPs) (48–51), potentially enabling noninvasive systemic gene therapy development for myriad neurological disorders afflicting broad CNS regions, such as NGLY1 deficiency.